Neurology

A panel of experts discuss the future of psychedelic medicine and the role of the pharmacy in that future.

Gabapentin enacarbil treats moderate-to-severe primary restless leg syndrome and postherpetic neuralgia.

Saol Therapeutics also announces the acquisition of 4 plasma-derived hyperimmune products by Kamada, which will be invested to help launch Lyvispah and other pipeline developments.

About 74% of individuals who remained on cenobamate had early-onset responder rates and high rates of sustained seizure reduction for as long as 43 months, study results show.

Febrile seizures occur in young, healthy children with normal development.

Ten quiz questions to assess your knowledge on common symptoms and treatments for Alzheimer disease.

Investigators have developed an antibody-based treatment for Alzheimer disease, as well as a protein-based vaccine.

Ron Aung-Din, MD, the clinical medical advisor of Pyscheceutical, and Chad Harman, the CEO of Pyscheceutical, discuss a novel approach for administering psychedelics for the treatment of brain disorders that does not induce hallucinogenic effects.

Ocrelizumab is indicated for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive disease, in adults.

Investigators from Michigan Medicine analyzed data from 16,700 individuals in a new study.

Tosymra is indicated for the acute treatment of migraine with or without aura in adults.

The guidance updates the recommendations on dopaminergic medications that were published in 2002 on the initiation treatment for Parkinson disease.

Approximately 40% of patients with stage IV melanoma have brain metastases at diagnosis.

Aducanumab-avwa is a human, immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta.

Patients were randomized 1:1 to receive either erenumab or topiramate, with the erenumab arm split into dosages of 70 mg or 140 mg.

Individuals taking erenumab had a 55.4% reduction from baseline in their monthly migraine days, results from HER-MES show.

A pharmacist can offer up to date knowledge on the clinical evidence behind new drugs, serving as a source of guidance for patients amongst the controversy with aducanumab and other new medications for Alzheimer disease.

Aducanumab-avwa is a monoclonal antibody that is the first treatment of its class designed to target the amyloid β protein, a biomarker of Alzheimer disease and other dementias.

Ten quiz questions to assess your knowledge on common symptoms and treatments for migraine headaches.

Agency gives green light to supplemental new drug application for repository corticotropin injection.

Atogepant is indicated for the preventive treatment of episodic migraine in adults.

According to the investigators, these new data support ofatumumab as a first-choice treatment for adult patients with RMS, including those who are newly diagnosed.

Midazolam is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity that are distinct from a patient’s usual seizure pattern in patients with epilepsy.

Gyang and Hansen discussed any new or existing treatment options for patients, the role of the pharmacist changing, and what they wish others knew about MS.

An effective therapeutic treatment for acute or chronic pain needs to be convenient, easy to self-administer, and have rapid onset to provide fast relief.

Pharmacy Times spoke with neurologist Dr. Tirisham Gyang and pharmacist Dr. Margaret Hansen about multiple sclerosis, including diagnosis, treatment options, and the role of the pharmacist in patient care.

Treatment options for autism spectrum disorder may include selective serotonin reuptake inhibitors, tricyclics, antipsychotics, stimulants, anti-anxiety medications, and anticonvulsants.

Early intervention with ocrelizumab resulted in a 35% reduction of risk in individuals with RMS who needed a walking aid over 7 and a half years.

Types of seizure include focal seizures with impaired awareness, generalized seizures without loss of consciousness, and generalized seizures, such as absence seizures.